Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Veracyte (VCYT) Receivables: 2012-2024

Historic Receivables for Veracyte (VCYT) over the last 13 years, with Dec 2024 value amounting to $46.5 million.

  • Veracyte's Receivables fell 2.01% to $47.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $198.9 million, marking a year-over-year increase of 6.87%. This contributed to the annual value of $46.5 million for FY2024, which is 15.22% up from last year.
  • According to the latest figures from FY2024, Veracyte's Receivables is $46.5 million, which was up 15.22% from $40.4 million recorded in FY2023.
  • Veracyte's 5-year Receivables high stood at $46.5 million for FY2024, and its period low was $18.5 million during FY2020.
  • Its 3-year average for Receivables is $43.6 million, with a median of $44.0 million in 2022.
  • In the last 5 years, Veracyte's Receivables spiked by 124.59% in 2021 and then fell by 8.28% in 2023.
  • Veracyte's Receivables (Yearly) stood at $18.5 million in 2020, then soared by 124.59% to $41.5 million in 2021, then grew by 6.17% to $44.0 million in 2022, then dropped by 8.28% to $40.4 million in 2023, then rose by 15.22% to $46.5 million in 2024.